Interim Report January – June 2021

Presentation at The Kempen & Co Life Sciences Conference

SynAct PharmaClinical Stage Biotech Company with focus on Resolution Therapy – A novel approach to fight inflammatory and auto-immune diseases

Lead compound AP1189 in Clinical Phase 2

Announcing additional Data from the Phase 2a Trial of AP1189 in Covid-19 Infected Patients

Press releases

October 15, 2021 - Non RegulatorySynAct Pharma doses first subject in study with new AP1189 tablets
October 15, 2021 - Non RegulatorySynAct Pharma doserar första försöksperson i studie med nya AP1189-tabletter
September 24, 2021 - RegulatorySynAct Pharma slutför rekryteringen till fas 2a studien BEGIN med AP1189 på nydebuterade patienter med akut reumatoid artrit
September 24, 2021 - RegulatorySynAct Pharma completes patient recruitment to the Phase 2a BEGIN study of AP1189 in early severe Rheumatoid Arthritis

All press releases

News

Donation to Reumatikerförbundet

Calendar

October 25, 2021 - October 27, 2021Bio Europe
November 9, 2021ACR Convergence 2021
November 12, 2021Interim report Q3 2021

Subscribe to our press releases